Glossary
REMS
FDA risk evaluation and mitigation strategy program.
Written by: Ira ZootMedically reviewed by: Ketalux Clinical Review PanelLast updated: June 4, 2026Evidence: Educational definition
REMS programs apply additional monitoring requirements to certain drugs. Esketamine (Spravato) is dispensed only under a REMS program requiring in-clinic administration and observation.
Related terms
- Esketamine (Spravato) — FDA-approved S-enantiomer of ketamine, delivered intranasally.
Definitions are educational and general. They are not medical advice.
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.